Target PharmaSolutions

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Target PharmaSolutions sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 1 currently recruiting 3 completed top decile by trial count

Target PharmaSolutions: 10 sponsored US clinical trials, 1 recruiting.

Target PharmaSolutions sponsors 10 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. The most-studied condition in this pipeline is Indeterminate Colitis, with 1 trials.

Top-decile sponsor footprint

Target PharmaSolutions ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING

A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

NCT02815891
ACTIVE NOT RECRUITING

An Observational Study of Patients With Chronic Gastrointestinal Disease

NCT05774080
ACTIVE NOT RECRUITING

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

NCT03661866
ACTIVE NOT RECRUITING

A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease

NCT03251118
ACTIVE NOT RECRUITING

A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

NCT02954094
COMPLETED

An Observational Study of Patients With Coronavirus Disease 2019

NCT04331886
TERMINATED

A Study of Patients With Chronic Disease

NCT04263727
TERMINATED

An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

NCT03692897
COMPLETED

Direct Acting Antiviral-Post Authorization Safety Study

NCT03707080
COMPLETED

A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis

NCT02932449

Therapeutic Areas

Indeterminate Colitis 1
Vitiligo 1
Hepatocellular Cancer 1
Nonalcoholic Fatty Liver 1
Nonalcoholic Steatohepatitis 1
Gastrointestinal Diseases 1
Chronic Spontaneous Urticaria 1
Alopecia Areata 1
Ulcerative Colitis 1
Inflammatory Bowel Diseases 1

What is open in the Target PharmaSolutions pipeline

1 recruiting of 10 indexed (10% open); 3 completed (30%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Indeterminate Colitis (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Target PharmaSolutions: open-pipeline peers nationwide

Peers matched on 10 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

Target PharmaSolutions sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 510152025 0%10%20%30%40% Total trials Recruiting share Target PharmaSolutionsAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAbiomedAimmune TherapeuticsAltria Client ServicesAlzheimer's Disease Cooperative Study (ADCS)
Target PharmaSolutions sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Target PharmaSolutions sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Target PharmaSolutions page

10 registered trials is a research-attention snapshot, not an endorsement of Target PharmaSolutions or any single study.

  • 1 of Target PharmaSolutions's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Indeterminate Colitis is the condition Target PharmaSolutions studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Indeterminate Colitis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Target PharmaSolutions pipeline card: 10 registered trials from official public datasets.Report a data error.